To evaluate the potential utility of fecal eosinophil-derived neurotoxin (fEDN) and lipocalin-2 (LCN-2) as non-invasive fecal biomarkers for screening and assessing pediatric inflammatory bowel disease (IBD), and to compare their sensitivity and specificity to fecal calprotectin (FC).
Approach:
Study Design: A case-control study conducted over 6 months involving 90 participants divided into three groups: IBD patients, healthy children, and children with acute diarrhea.
Patient Evaluation: Included comprehensive history taking, clinical examination, and laboratory investigations to assess the participants.
Key Findings:
Fecal eosinophil-derived neurotoxin (fEDN) and lipocalin-2 (LCN-2) are stable in feces for at least 7 days at room temperature, indicating their potential as non-invasive biomarkers.
High fecal concentrations of fEDN are associated with active ulcerative colitis and Crohn’s disease, as observed in the study.
Increased LCN-2 expression was documented in inflamed intestinal epithelial cells of IBD patients, supporting its potential role in disease assessment.
Interpretation:
The study aims to compare the diagnostic efficacy of fEDN and LCN-2 with fecal calprotectin (FC) in diagnosing and assessing IBD in children.
Limitations:
The study is limited to a specific population and may not be generalizable to all pediatric IBD patients.
Exclusion criteria may limit the diversity of the sample.
Conclusion:
The study aims to evaluate the role of fEDN and LCN-2 as complementary biomarkers in the assessment of pediatric IBD.
